These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 808594)

  • 1. Chemistry of technetium radiopharmaceuticals. I. Exploration of the tissue distribution and oxidation state consequences of technetium (IV) in Tc-Sn-gluconate and Tc-Sn-EHDP using carrier 99Tc.
    Hambright P; McRae J; Valk PE; Bearden AJ; Shipley BA
    J Nucl Med; 1975 Jun; 16(6):478-82. PubMed ID: 808594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 99mTc-labelled compounds prepared with sodium dithionite as reducing agent.
    Vilcek S; Kalincák M; Machán V
    Nuklearmedizin; 1981 Dec; 20(6):283-9. PubMed ID: 6460222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemistry of 99mTc tracers. II. In vitro conversion of tagged HEDP and pyrophosphate (bone-seekers) into gluconate (renal agent). Effects of Ca and Fe (ii) on in vivo distribution.
    McRae J; Hambright P; Valk P; Bearden AJ
    J Nucl Med; 1976 Mar; 17(3):208-11. PubMed ID: 175138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complexing of reduced technetium and tin(II) by chelating phosphate compounds. II. In vitro stability of pyrophosphate and ethane-1, hydroxy-1, diphosphonate (EHDP) complexes.
    Schümichen C; Hohloch M; Hoffmann G
    Nuklearmedizin; 1979 May; 18(2):105-9. PubMed ID: 38437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complexing of reduced technetium and tin (II) by chelating phosphate compounds. I. Chemical state of technetium.
    Schümichen C; Hohloch H; Schiller A; Pohle W; Hoffmann G
    Nuklearmedizin; 1979 May; 18(2):98-104. PubMed ID: 38438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparison of osteotropic radiopharmaceuticals. II. Plasma clearance of 18F and 99mTc-EHDP (author's transl)].
    Creutzig H
    Rofo; 1975 Oct; 123(4):313-8. PubMed ID: 129388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting uptake and retention of technetium-99m-diphosphonate and 99m-pertechnetate in osseous, connective and soft tissues.
    Francis MD; Slough CL; Tofe AJ
    Calcif Tissue Res; 1976 Jun; 20(3):303-11. PubMed ID: 182328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexes of technetium with pyrophosphate, etidronate, and medronate.
    Russell CD; Cash AG
    J Nucl Med; 1979 Jun; 20(6):532-7. PubMed ID: 43885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and biological distribution of technetium diphosphonate radiotracers synthesized without stannous ion.
    Deutsch E; Libson K; Becker CB; Francis MD; Tofe AJ; Ferguson DL; McCreary LD
    J Nucl Med; 1980 Sep; 21(9):859-66. PubMed ID: 6774066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter: Toxicity of 99mTc-Sn-EHDP.
    Hattner RS
    J Nucl Med; 1975 May; 16(5):444-5. PubMed ID: 811773
    [No Abstract]   [Full Text] [Related]  

  • 11. Uptake of Tc-99m monophosphate complexes in bone and myocardial necrosis in animals.
    Kung HF; Ackerhalt R; Blau M
    J Nucl Med; 1978 Sep; 19(9):1027-31. PubMed ID: 690703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dose distribution of bone-seeking radiopharmaceuticals in the rat (author's transl)].
    Schümichen C; Hermannsdörfer A; Wüst H; Hoffmann G
    Strahlentherapie; 1979 Nov; 155(11):796-801. PubMed ID: 117574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 99mTc-labelled compounds prepared with antimony(III) as reducing agent.
    Vilcek S; Machán V; Kalincák M
    Radiobiol Radiother (Berl); 1983; 24(1):103-8. PubMed ID: 6407061
    [No Abstract]   [Full Text] [Related]  

  • 14. 99mTc-labelled Cu(I)-EHDP, a potential skeletal imaging agent.
    Agha NH; Al-Hilli AM; Hassen HA
    Nuklearmedizin; 1981 Dec; 20(6):299-304. PubMed ID: 6799937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A possible artifact in gel chromatography of some 99m Tc-chelates.
    Valk PE; Dilts CA; McRae J
    J Nucl Med; 1973 Apr; 14(4):235-7. PubMed ID: 4691415
    [No Abstract]   [Full Text] [Related]  

  • 16. [Whole-body autoradiography for the characterization of 99mTc-radiopharmaceuticals: an investigation on Tc (V)-dithiolato-complexes (author's transl)].
    Kretzschmar M; Johannsen B
    Radiobiol Radiother (Berl); 1979 Dec; 20(6):777-84. PubMed ID: 547306
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of high performance liquid chromatography for the structural identification of technetium-99m radiopharmaceuticals at the NCA level.
    Baldas J; Bonnyman J; Ivanov Z
    J Nucl Med; 1989 Jul; 30(7):1240-8. PubMed ID: 2738705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of bone metastases with 99m Tc-Sn-EHDP (diphosphonate), 18 F, and skeletal radiography. A comparison of sensitivity.
    Silberstein EB; Saenger EL; Tofe AJ; Alexander GW; Park HM
    Radiology; 1973 Jun; 107(3):551-5. PubMed ID: 4633984
    [No Abstract]   [Full Text] [Related]  

  • 19. Structural characterization of a bridged 99Tc-Sn-dimethylglyoxime complex: implications for the chemistry of 99mTc-radiopharmaceuticals prepared by the Sn (II) reduction of pertechnetate.
    Deutsch E; Elder RC; Lange BA; Vaal MJ; Lay DG
    Proc Natl Acad Sci U S A; 1976 Dec; 73(12):4287-9. PubMed ID: 1069984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the Tc-nitrido group on the behaviour of 99mTc-radiopharmaceuticals.
    Baldas J; Bonnyman J
    Int J Appl Radiat Isot; 1985 Dec; 36(12):919-23. PubMed ID: 3936786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.